Highlights of the Program

2 days business program:

Learn from real-world case studies by industry leaders.

SHOWCASING INNOVATION:

Discover the latest technology and techniques from across the industry.

leaders talk:

Hear from top-level experts about how to stay ahead in a fast-changing industry.

MULTIPLE STREAMS:

A business program that is multi-disciplinary, giving you a broad view of the industry.

SMART TECHNOLOGIES:

Explore the latest smart and AI-driven solutions, and see how they can be used in your business.

roundtable discussion:

Join talks with industry peers. Share ideas, make connections, and find new partners.

Program

DAY 1 :

WEDNESDAY, 22 JULY, 2026

08:00 - 08:50

REGISTRATION AND MORNING REFRESHMENTS

08:50 - 09:00

OPENING ADDRESS

09:00 - 09:25

NOVEL APPROACH TO IDENTIFY BIOMARKERS FOR mRNA-BASED THERAPEUTICS AND VACCINES

Fredrik Sundberg

Standard BioTools

Spotlighting market trends and biomarker gaps for safer, more effective mRNA modalities
Correlating richer biological data with stratification decisions and clinical outcome signals
Extracting auto-antibody biomarker insights from post-COVID and vaccine case studies

09:25 - 09:30

Q&A SESSION ON BIOMARKERS FOR mRNA THERAPEUTICS AND VACCINES

09:30 - 09:55

PROGRAMMING BIOLOGY: BREAKTHROUGHS IN mRNA MEDICINES, OLIGONUCLEOTIDE THERAPEUTICS, AND NANOBODY-ENABLED TARGETING

Nicholas Collette

CELLEQORE

Showcasing mRNA and oligo breakthroughs spanning oncology, neurology, and in vivo reprogramming
Widening RNA medicine reach using nanobody targeting for delivery and in vivo CAR-T generation
Framing mRNA oligos and nanobodies as a convergent modular toolkit for next-decade therapies

09:55 - 10:00

Q&A SESSION ON BREAKTHROUGHS IN RNA AND NANOBODY MEDICINES

10:00 - 10:25

ESTABLISHING AN “RNA COOPERATIVE” TO CO-DEVELOP AN mRNA VACCINE

Jens Demand

PATH

Empowering LMIC manufacturers with hands-on RNA vaccine expertise and shared resources
Pooling members across regions to co-develop candidates and strengthen RNA vaccine portfolios
Mentoring teams toward Phase 1 readiness through collaborative tech transfer and trial planning

10:25 - 10:30

Q&A SESSION ON PATH’S RNA COOPERATIVE FOR mRNA VACCINE CO-DEVELOPMENT

10:30 - 11:00

MORNING COFFEE BREAK IN THE EXHIBIT AREA

11:00 - 11:30

PANEL DISCUSSION ON AI/ML-DRIVEN ADVANCEMENTS IN RNA THERAPEUTICS MANUFACTURING

11:30 - 11:55

ENABLING RAPID mRNA VACCINE DEVELOPMENT WITH CELL-FREE DNA TEMPLATES FOR PANDEMIC PREPAREDNESS

Anusha Dias

Sanofi

Replacing plasmids with cell-free DNA to speed IVT template supply without endotoxin risks
Optimising rolling circle amplification to yield long linear constructs with high sequence fidelity
Integrating enzymatic digestion and mRNA characterisation to cut timelines and improve flexibility

11:55 - 12:00

Q&A SESSION ON cfDNA TEMPLATES FOR RAPID mRNA VACCINES

12:00 - 12:25

MRNA SEQUENCE DESIGN AND mRNA-BASED IN VIVO CAR-T THERAPEUTICS

Zhongyao Ma

WuXi AppTec

Designing combinatorial LNP libraries and screening candidates for in vivo delivery performance
Refining mRNA sequences and UTRs to improve expression, stability, and activity
Demonstrating in vivo CAR-T generation using mRNA-tLNPs through a focused case study programme

12:25 - 12:30

Q&A SESSION ON mRNA DESIGN FOR IN VIVO CAR-T THERAPEUTICS

12:30 - 13:30

NETWORKING LUNCH AND VISITING THE mRNA CONFERENCE EXHIBITION

13:30 - 13:55

AI-DRIVEN DESIGN AND IMMUNOPEPTIDOMIC CHARACTERISATION OF mRNA VACCINE CANDIDATES

Alexandru Odainic

NEC Bio

Harnessing AI-based antigen ordering to guide computational mRNA vaccine candidate design
Mapping peptide presentation landscapes following mRNA vaccine transfection via immunopeptidomics
Bridging computational and experimental methods to accelerate multipayload mRNA construct design

13:55 - 14:00

Q&A SESSION ON AI AND IMMUNOPEPTIDOMICS IN mRNA VACCINE DISCOVERY

14:00 - 14:25

ADVANCING RNA THERAPEUTICS WITH SENS™ POLYMER–LIPID HYBRID NANOPARTICLES

Sunny Song

Samyang Biopharm

Deploying SENS™ hybrid nanoparticles for tissue-selective RNA therapeutic delivery
Engineering biodegradable polymer and ionisable lipid cores to balance potency and safety
Targeting spleen, lung, muscle, CNS, and liver while supporting repeat dosing profiles

14:25 - 14:30

Q&A SESSION ON HYBRID NANOPARTICLES FOR RNA DELIVERY

14:30 - 14:55

NEXT-GENERATION RNA MEDICINE FOR LOWER-COST, HIGHER-QUALITY IN VIVO CANCER THERAPEUTICS AND VIRAL VACCINES

Parker Moss

Wellcome Leap

Scaling distributed RNA biofoundries to replace slow, costly biologics with rapid RNA output
Automating codon optimisation and continuous-flow RNA manufacturing to boost expression and fidelity
Encoding CAR-T BiTEs and personalised vaccines to cut cost and speed translation to scale

14:55 - 15:00

Q&A SESSION ON LOWER-COST IN VIVO RNA CANCER THERAPIES

15:00 - 15:20

AFTERNOON COFFEE BREAK IN THE EXHIBIT AREA

15:20 - 15:45

FROM PLASMID TO PATIENT: GMP CONSIDERATIONS AND CMC STRATEGIES FOR mRNA SCALE-UP

Nishant Soni

CoJourney

Orchestrating GMP tech transfer and scale-up to streamline mRNA production readiness
Standardising pDNA design and supply to strengthen CMC success for mRNA therapeutics
De-risking COGs and manufacturing strategy by aligning plasmid processes with scale goals

15:45 - 15:50

Q&A SESSION ON GMP AND CMC STRATEGIES FOR mRNA SCALE-UP

15:50 - 16:15

THERAPEUTIC NUCLEIC ACIDS - ADVANCED SOLUTIONS FOR DOWNSTREAM PROCESSING AND ANALYTICS

Elena Kumm

Tosoh Bioscience GmbH

Refining chromatographic methods tailored for high-purity therapeutic oligonucleotides
Purifying across impurity classes from shortmers and longmers to process-related contaminants
Reviewing case studies to guide strategy selection and optimisation for robust downstream workflows

16:15 - 16:20

Q&A SESSION ON OLIGO DOWNSTREAM PROCESSING AND ANALYTICS

16:20 - 16:45

NOVEL RIG-I-AGONIST-ADJUVANT FOR TUNABLE INNATE IMMUNE STIMULATION BY mRNA VACCINES

Svenja Dudek

University Hospital Bonn

Minimizing dsRNA byproducts by tuning IVT templates and coding composition for clean mRNA
Hybridizing RIG-I ligands to the mRNA 3’UTR to deliver controllable innate co-stimulation
Balancing translation with type I IFN signaling to boost T and B cell responses
Lowering purification requirements to avoid inflammatory side effects of dsRNA by-products

16:45 - 16:50

Q&A SESSION ON TUNABLE RIG-I ADJUVANT FOR mRNA VACCINES

16:50 - 17:15

ADVANCING mRNA LNP PRODUCT QUALITY: A CQA-DRIVEN APPROACH TO ANALYTICAL CHARACTERIZATION AND STABILITY ASSESSMENT

Manuel Alfaro

National Institute for Bioprocessing Research & Training

Implementing QbD with defined CQAs to assure consistent mRNA LNP quality and safety
Assessing integrity and potency using CE, HPLC, MS, NGS, and standardised assays
Harmonising stability testing and reference standards to support lifecycle compliance worldwide

17:15 - 17:20

Q&A SESSION ON CQA-DRIVEN mRNA LNP QUALITY STRATEGY

17:20 - 18:20

NETWORKING DRINKS RECEPTION

DAY 2 :

THURSDAY, 23 JULY, 2026

08:00 - 08:30

MORNING REFRESHMENTS

08:30 - 08:40

OPENING ADDRESS

08:40 - 09:05

SUSTAINABLE LARGE-SCALE mRNA BIOPROCESSING

Tia Lyles-Williams

Goffman Bougard, Inc.

Intensifying production with continuous-flow modules and in situ product removal
Reusing immobilised DNA templates for solid-phase IVT to cut plasmid DNA costs sharply
Capping co-transcriptionally to boost recovery and reduce reagent spend versus enzymes
Precipitating and filtering in continuous-flow DSP to replace chromatography and cut waste

09:05 - 09:10

Q&A SESSION ON SUSTAINABLE LARGE-SCALE mRNA BIOPROCESSING

09:10 - 09:35

INTRANASAL mRNA VACCINE: TARGETING THE FRONT LINES OF RESPIRATORY VIRUS DEFENCE

Sudha Chivukula

Sanofi

Protecting airways by inducing mucosal immunity where respiratory viruses first replicate
Eliciting robust pulmonary immune responses through intranasal dosing rather than traditional injections
Reducing influenza and RSV viral loads across species to help stop infection at the source

09:35 - 09:40

Q&A SESSION ON INTRANASAL mRNA VACCINES

09:40 - 10:05

PATENT STRATEGY FOR RNA THERAPEUTICS IN EUROPE AND THE US

Ross Cummings

Gill Jennings & Every LLP

Clarifying EU and US patent eligibility boundaries for RNA sequences and modification
Structuring claim strategies across RNA types, using sequence plus chemistry combinations
Evidencing inventions with the right experimental data, knowing when and what to show

10:05 - 10:10

Q&A SESSION ON PATENT STRATEGY FOR RNA THERAPEUTICS

10:10 - 10:30

MORNING COFFEE BREAK IN THE EXHIBIT AREA

10:30 - 10:55

ONE ASSAY TO RULE THEM ALL: REPLACING MULTI-METHOD mRNA QC WITH A SINGLE NANOPORE WORKFLOW

Michael Hanson

Oxford Nanopore Technologies

Streamlining mRNA QC by replacing CE, HPLC, and gels with a single nanopore workflow
Consolidating identity, integrity, capping, poly-A tail, and dsRNA metrics in one run
Justifying GMP adoption with cost comparisons and regulatory defensibility for batch release

10:55 - 11:00

Q&A SESSION ON A SINGLE NANOPORE WORKFLOW FOR mRNA QC

11:00 - 11:25

ENHANCING mRNA THERAPEUTICS: INNOVATIONS IN PURIFICATION, IVT OPTIMISATION, AND DELIVERY

Érica Schulze

Sartorius

Isolating high-quality plasmid DNA with advanced methods that strengthen IVT inputs
Optimising IVT conditions to improve mRNA yield, integrity, and reproducibility at scale
Clearing mRNA impurities using purification workflows that protect downstream performance
Tuning LNP formulation parameters that shape delivery potency and tolerability profiles

11:25 - 11:30

Q&A SESSION ON mRNA BIOPROCESSING AND DELIVERY

11:30 - 11:55

NEXT GENERATION MRNA NANOPARTICLES FOR VACCINATION AND THERAPY

Heinrich Haas

NeoVac

Upgrading NeoVac lipids to improve safety, immunogenicity, and CMC versus current LNPs
Resolving delivery limits to enable a broader range of mRNA vaccines and therapeutics
Validating Phase I/II results showing safer profiles than licensed mRNA products in humans

11:55 - 12:00

Q&A SESSION ON NEXT-GEN NANOPARTICLES FOR MRNA DELIVERY

12:00 - 12:25

EUROPEAN PATENTS – THE UNIFIED PATENT COURT, OPPOSITIONS AND MORE

Thomas Ricketts

Boult Wade Tennant LLP

Explaining how the Unified Patent Court has evolved since its launch and early case learnings
Comparing opt-out choices and Unitary Patents for securing broad protection across Europe
Navigating validity and infringement routes across EPO, UPC, and national courts in key markets

12:25 - 12:30

Q&A SESSION ON UPC STRATEGY AND EUROPEAN PATENT ENFORCEMENT

12:30 - 13:30

NETWORKING LUNCH & VISIT THE MRNA CONFERENCE EXHIBITION

13:30 - 13:55

ACCELERATING mRNA THERAPEUTIC DEVELOPMENT AND OPTIMISATION THROUGH PREDICTIVE MECHANISTIC MODELING

Luca Marchetti

Centre for Computational and Systems Biology (COSBI)

Predicting development outcomes with mechanism-driven models that speed mRNA translation to the clinic
Guiding candidate selection and translation plans across delivery routes and therapeutic modalities
Adjusting dose schedule and product design to shorten timelines and raise clinical success odds

13:55 - 14:00

Q&A SESSION ON PREDICTIVE MECHANISTIC MODELING FOR mRNA THERAPEUTICS

14:00 - 14:25

MECHANISM AND PREVENTION OF SYSTEMIC INFLAMMATION CAUSED BY mRNA VACCINES

János Szebeni

Semmelweis University

Unpacking rare inflammatory organ-level events seen after mRNA LNP vaccination, including myopericarditis
Modelling off-target LNP distribution that drives multiorgan spike expression and autoimmune injury
Preventing adverse events using porcine in vivo studies to test mitigation strategies for safer dosing

14:25 - 14:30

Q&A SESSION ON PREVENTING INFLAMMATION AFTER mRNA VACCINES

14:30 - 14:55

COMBINING MACHINE LEARNING AND MOLECULAR DYNAMICS SIMULATIONS TO SUCCESSFULLY DISCOVER AND OPTIMISE LNP FORMULATIONS FOR RNA DELIVERY

Felix Sieber-Schäfer

LMU München

Accelerating LNP discovery by combining meta-learning and active learning with simulation signals
Fusing molecular dynamics features with ML to improve formulation selection beyond DoE limits
Outperforming standard ML and DoE on benchmarks while tackling transfection cliffs

14:55 - 15:00

Q&A SESSION ON AI-DRIVEN LNP DESIGN FOR RNA DELIVERY

15:00 - 15:15

FEEDBACK AND RAFFLE DRAW

15:15 - 15:30

CLOSING REMARKS

Become a Speaker & Join the Conversation

SUBSCRIBE FOR UPDATES

By submitting, you agree to receive email communications from the event organizers, including upcoming promotions and discounted tickets, news, and access to related events.